proliferation within specific structures known as proliferation centers. The tissue microenvironment is thus believed to play a critical role in CLL disease progression. [3] [4] [5] Indeed, a bulky lymphadenopathy is a feature of advanced disease correlating with poor clinical outcome.
Importantly, CLL cell migration to LNs provides protection from chemotherapy and immunotherapy. 6 Interfering with CLL cell migration or retention in LNs could thus result in a greater efficacy of conventional therapy for advanced CLL patients.
Several chemokine receptors have been proposed to play important roles in CLL cell trafficking (i.e. CXCR4, CXCR5 and CCR7). 5, 7 CXCR4, the receptor for CXCL12, was the first chemokine receptor shown to be expressed and functional on CLL cells. 8 CLL cells were later found to express high levels of CCR7 9,10 and CXCR5 10-12 , the receptors for chemokines CCL19/CCL21 and CXCL13, respectively. In vitro chemotaxis assays have revealed that CLL cells efficiently migrate in response to all ligands of CCR7, CXCR4 and CXCR5. [8] [9] [10] [11] [12] Together, these studies suggested that lymphoid chemokines and their receptors, which play critical roles in B cell homing to LNs and other secondary lymphoid organs, are likely to be also important for CLL cell migration in vivo.
8-12
Despite these important advances on the role of chemokine receptors in CLL cell trafficking, the mechanisms regulating CLL cell migration in vivo remain incompletely characterized. For instance, it is currently unknown which molecules control the initial capture
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13,14 B lymphocytes use a multi-step adhesion cascade (rolling, sticking, crawling) to attach to HEV walls in vivo. 13 Whether CLL cells exhibit a similar behavior has not yet been determined. Here, we used an in vivo imaging approach to address these unresolved and important issues. Intravital microscopy analysis of the mouse LN microcirculation 14,15 allowed us to visualize for the first time the rolling, sticking and crawling of human CLL cells on HEV endothelium in vivo, and to demonstrate the critical role of the lymphocyte homing receptor Lselectin (CD62L) [16] [17] [18] in these processes. Interestingly, we observed downregulation of L-selectin on CLL cells from patients under treatment with the phosphoinositide 3-kinase δ inhibitor idelalisib 19, 20 suggesting an inhibitory effect of this drug on CLL cell migration to LNs.
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Histology and confocal microscopy
LNs were either fixed in 10% formalin and embedded in paraffin or embedded in optimal cuttingtemperature compounds and snap-frozen in liquid nitrogen. 3-µm thick sections were used for histology and 5-µm thick sections for confocal microscopy. HEV density and HEV pockets were
For personal use only. on June 9, 2017. by guest www.bloodjournal.org From 8 analyzed using the HEV-specific antibody MECA-79 (ATCC). The detailed procedures and antibodies used are described in supplemental Methods. Panoramic Viewer and HistoQuant software were used for respectively viewing and analyzing the digitalized slides (RTM 1.5.053.3D Histech, Budapest, Hungary).
Flow Cytometry
Freshly isolated PBMC were incubated with the following fluorochrome-conjugated Abs, CD19- 
Statistics
Data are shown as mean ± SD or mean ± SEM (as indicated) and were analyzed using a 2-tailed unpaired Student's t test. When indicated, a 2-tailed paired Student's t test or Mann-Whitney test were instead applied. Differences were considered statistically significant when P < 0.05. 
CD20 + CLL cells accumulate within HEV pockets in CLL LNs
To analyze the HEV network, we stained human CLL and control LNs with the HEV-specific Ab MECA-79 which recognizes sulfated ligands for lymphocytes ( Figure 1A ). HEV density was significantly increased in CLL LNs (n=13) and small lymphocytic lymphoma (SLL) LNs Table 1 , Videos 1 and 2) than for CLL cells from patients without bulky disease (Table 1 , Video 3). Indeed, 60% of the CLL cells from patients with bulky disease rolled in order V HEVs and more than 10% of these cells arrested, compared to less than 30% and 3%, respectively, for CLL cells from patients with no bulky disease ( Figure 3B ). In addition, CLL cells from patients with bulky disease rolled more slowly in HEVs than cells from patients without bulky disease ( Figure 3C ). Intravital two-photon laser scanning microscopy revealed that after arrest, CLL cells were able to crawl on the HEV endothelium, some of them in the opposite direction of blood flow ( Figure 3D and Video 4). The average intraluminal velocity of the CLL cells was ~ 6 μm/min ( Figure 3E ). This velocity is 1 1 similar to that of murine B cells in LN HEVs. 26 We concluded that human CLL cells are able to roll, stick and crawl on HEV endothelium in vivo.
The lymphocyte homing receptor L-selectin controls the adhesion of CLL cells to HEV walls in vivo
We then investigated the molecular mechanisms controlling the behavior of CLL cells within LN HEVs. We first analyzed the expression of the lymphocyte homing receptor L-selectin, 17,18 which mediates the initial capture and rolling interactions of lymphocytes on HEV endothelium, 13, 16, 27, 28 and is known to be expressed on CLL cells. 29, 30 We found that L-selectin is expressed at significantly higher levels on CLL cells from patients with bulky disease compared to cells from patients without bulky disease ( Figure 4A ). In contrast, similar expression levels between the two subgroups of patients were observed for chemokine receptor CXCR4 and integrin LFA-1, which mediates the sticking of lymphocytes to HEV endothelial cells. 13 In the course of these studies,
we identified a third subgroup of patients with bulky disease but lower circulating lymphocyte counts (< 40 000 cells/mm 3 ; CLL/SLL patients BL01-03, Table 1 ). Interestingly, CLL/SLL cells from this subgroup expressed low levels of L-selectin and had a reduced capacity to roll and stick to HEVs ( Figure S1 ), compared to CLL cells from patients with bulky disease and high circulating lymphocyte counts (> or = 40 000 cells/mm 3 ; CLL patients BL15-BL24, Table 1 ).
Together, these results suggested that differences in L-selectin expression could explain the 
observed and it was dependent on L-selectin ( Figure 4C and D) . In addition, we observed low Lselectin expression and reduced rolling and sticking fractions for cells from patients with bulky disease but lower circulating lymphocytes counts (< 40 000 cells/mm 3 , including one SLL patient; Figure S1 ). These patients may thus have a defect in CLL/SLL cell entry in LNs through
HEVs. L-selectin expression was also decreased on CLL cells from patients after treatment with idelalisib in vivo ( Figure 5A ) and this was associated with increased rolling velocity ( Figure 5C 
that they rapidly de-differentiate outside the lymphoid tissue microenvironment. 34 In addition, no human HEV cell line or cultured human endothelial cells that exhibit the bona fide HEV phenotype (i.e. expressing the sulfated ligands recognized by L-selectin and HEV-specific mAb MECA-79), have been described yet.
We found that the density of HEVs was increased in human CLL LNs and that CD20 + CLL cells frequently accumulated within HEV pockets (Figure 2 ). To the best of our knowledge, this is the first description of HEV pockets in human LNs. In mouse LNs, HEV pockets have been shown to function as "waiting areas" in which lymphocytes were held until space was made available to them for entry into the LN tissue. 23 They were found to be highly dynamic structures that are continuously altered in size and location by lymphocyte migration. Interestingly, an
antibody that blocks L-selectin-mediated lymphocyte entry in LNs through HEVs, induced the disappearance of HEV pockets in vivo. 23 Therefore, the presence of many HEV pockets occupied by CLL cells in human CLL LNs strongly suggest that HEVs mediate high levels of CLL cell entry in LNs.
In this study, we have focused on CLL cell entry (or re-entry) in LNs. However, another key aspect in CLL cell trafficking is the egress from LNs. In normal B cells, this process depends on the sphingosine-1 phosphate receptor S1PR1, 13,26 a receptor which has been shown to be reduced on CLL cells from patients with unfavorable prognosis. 35 Defective egress caused by impaired S1PR1 expression was proposed to contribute to the extended survival of CLL cells by prolonging their residency in the prosurvival niche of LNs. 35 Egress occurs only minimally in SLL, and differential expression of S1PR1 may also explain some of the differences between CLL and SLL. Interestingly, idelalisib has recently been shown to increase S1PR1 expression on CLL cells, 36 an effect that could contribute to the rapid resolution of lymphadenopathy (LN shrinkage) and redistribution of CLL cells into the blood (lymphocytosis) that have been For personal use only. on June 9, 2017. by guest www.bloodjournal.org From 1 7
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